Peripheral neurotoxicity of taxol in patients previously treated with cisplatin
- PMID: 7850713
- DOI: 10.1002/1097-0142(19950301)75:5<1141::aid-cncr2820750514>3.0.co;2-u
Peripheral neurotoxicity of taxol in patients previously treated with cisplatin
Abstract
Background: Taxol is a new anticancer drug that acts as a tubulin polymeration enhancer. Its major toxicities are myelosuppression, hypersensitivity, and mucositis, but it also induces peripheral nerve damage. The use of taxol has recently been proposed for platinum-resistant cancers, but in these cases there is a possibility of cumulative toxicity in the peripheral nervous system.
Methods: Twenty-two patients affected by a relapse of cisplatin-treated ovarian cancer were examined clinically and neurophysiologically to determine the evolution of taxol-induced peripheral somatic and autonomic neurotoxicity and the possible cumulative effect of a combination of taxol and cisplatin. Each patient was examined before, during, and after taxol treatment (using a dose of 135 or 175 mg/m2 in 3 hours every 3 weeks).
Results: No patients were excluded from the study because of unacceptable toxicities of any kind. The serial examinations demonstrated that taxol induced onset of (or worsening of preexisting) neuropathic symptoms and signs in almost all the patients. The features were those of a distal, symmetrical, sensory polyneuropathy due to an axonopathy. Motor nerves and the autonomic nervous system were unaffected. Taxol neurotoxicity appeared early in the course of the treatment (i.e., after three courses) and was not severely disabling. In most cases after the early onset of peripheral neuropathy, stabilization of this side effect occurred.
Conclusions: Considering the low doses of taxol used in this study, the sensory nerve damage was unexpectedly severe. It appears that a cumulative, but not dose-limiting, neurotoxic effect occurs using taxol in patients previously treated with cisplatin.
Comment in
-
Peripheral neurotoxicity of taxol in patients previously treated with cisplatin.Cancer. 1995 Sep 1;76(5):916-7. doi: 10.1002/1097-0142(19950901)76:53.0.co;2-v. Cancer. 1995. PMID: 8625200 No abstract available.
Similar articles
-
Peripheral neuropathy from taxol and cisplatin combination chemotherapy: clinical and electrophysiological studies.Ann Neurol. 1994 Mar;35(3):304-11. doi: 10.1002/ana.410350310. Ann Neurol. 1994. PMID: 7907208
-
Neurological monitoring of neurotoxicity induced by paclitaxel/cisplatin chemotherapy.Eur J Cancer. 1997 Aug;33(9):1393-9. doi: 10.1016/s0959-8049(97)00103-2. Eur J Cancer. 1997. PMID: 9337680 Clinical Trial.
-
Neurotoxicity of Taxol.J Natl Cancer Inst Monogr. 1993;(15):107-15. J Natl Cancer Inst Monogr. 1993. PMID: 7912516 Review.
-
Phase I dose escalation of paclitaxel in patients with advanced ovarian cancer receiving cisplatin: rapid development of neurotoxicity is dose-limiting.J Clin Oncol. 1997 May;15(5):1965-73. doi: 10.1200/JCO.1997.15.5.1965. J Clin Oncol. 1997. PMID: 9164208 Clinical Trial.
-
Clinical toxicities encountered with paclitaxel (Taxol).Semin Oncol. 1993 Aug;20(4 Suppl 3):1-15. Semin Oncol. 1993. PMID: 8102012 Review.
Cited by
-
Persistent chemoneuropathy in patients receiving the plant alkaloids paclitaxel and vincristine.Cancer Chemother Pharmacol. 2013 Mar;71(3):619-26. doi: 10.1007/s00280-012-2047-z. Epub 2012 Dec 11. Cancer Chemother Pharmacol. 2013. PMID: 23228992 Free PMC article.
-
Peripheral neuropathy due to therapy with paclitaxel, gemcitabine, and cisplatin in patients with advanced ovarian cancer.J Neurooncol. 2003 Jun;63(2):201-5. doi: 10.1023/a:1023952106955. J Neurooncol. 2003. PMID: 12825825
-
The relationship between numbness, tingling, and shooting/burning pain in patients with chemotherapy-induced peripheral neuropathy (CIPN) as measured by the EORTC QLQ-CIPN20 instrument, N06CA.Support Care Cancer. 2012 Mar;20(3):625-32. doi: 10.1007/s00520-011-1141-9. Epub 2011 Apr 12. Support Care Cancer. 2012. PMID: 21479990 Free PMC article. Clinical Trial.
-
Chemotherapy-induced painful neuropathy: pain-like behaviours in rodent models and their response to commonly used analgesics.Curr Opin Support Palliat Care. 2016 Jun;10(2):119-128. doi: 10.1097/SPC.0000000000000204. Curr Opin Support Palliat Care. 2016. PMID: 27054288 Free PMC article. Review.
-
An updated understanding of the mechanisms involved in chemotherapy-induced neuropathy.Pain Manag. 2018 Sep 1;8(5):363-375. doi: 10.2217/pmt-2018-0020. Epub 2018 Sep 13. Pain Manag. 2018. PMID: 30212277 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Medical